VCAM1 Antibodies

Structure of VCAM1

VCAM1 is a transmembrane glycoprotein with a molecular weight of approximately 81-110 kDa. Its differences mainly stem from variations in gene splicing and glycosylation modifications among different species.

The extracellular region of this protein contains 6 to 7 immunoglobulin-like domains, among which the 1st and 4th domains are the key regions for binding to integrins. Its tertiary structure forms a rigidly extended rod-like conformation and is anchored to the cell membrane through transmembrane regions. N-terminal glycosylation modification plays an important regulatory role in protein stability and ligand recognition, while the phosphorylation of serine residues at the cytoplasmic tail is involved in the regulation of intracellular signal transduction processes.

Fig. 1 The structure of VCAM-1 and its α4β1 integrin binding regions.¹

Key structural properties of VCAM1:

• Extracellular immunoglobulin-like domains are repeatedly arranged
• Rigidly extended rod-shaped spatial conformation
• Specific integrin binding interface

Functions of VCAM1

The core function of VCAM1 is to mediate the adhesion and migration of immune cells to vascular endothelium. However, this molecule is also involved in a variety of pathophysiological processes, including inflammatory signal transduction and regulation of the immune microenvironment.

The binding of VCAM1 to integrins exhibits dynamically tunable characteristics, and its affinity is regulated by both the cytokine microenvironment and the glycosylation status. This feature makes it an important intervention target for inflammatory and immune diseases.

Applications of VCAM1 and VCAM1 Antibody in Literature

1. Perner, Caroline, et al. "Plasma VCAM1 levels correlate with disease severity in Parkinson's disease." Journal of neuroinflammation 16.1 (2019): 94. https://doi.org/10.1186/s12974-019-1482-8

Research has found that the expression of VLA4 in patients with Parkinson's disease is down-regulated, the level of plasma sVCAM1 is significantly increased, and it is related to the degree of movement disorder, suggesting dysfunction of the VCAM1-VLA4 axis.

2. Hession, Catherine, et al. "Cloning of an alternate form of vascular cell adhesion molecule-1 (VCAM1)." Journal of Biological Chemistry 266.11 (1991): 6682-6685. https://doi.org/10.1016/S0021-9258(20)89551-9

Research has found that VCAM1 exists in two mRNA forms, long and short, which are produced by alternative splicing. The long type is the main form of existence, and both can mediate VLA-4 integrin-dependent immune cell adhesion.

3. Wang, Tongyu, Jiahu Tian, and Yuanzhe Jin. "VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium." Scientific Reports 11.1 (2021): 19488. https://doi.org/10.1038/s41598-021-98998-3

Research has found that VCAM1 plays a core role in heart failure caused by ischemic and dilated cardiomyopathy. Its expression disorder is associated with immune cell infiltration and the risk of disease, and it may serve as a potential biomarker and therapeutic target.

4. Uosaki, Hideki, et al. "Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression." PloS one 6.8 (2011): e23657.https://doi.org/10.1371/journal.pone.0023657

Research has found that VCAM1 can serve as a highly specific surface marker for human stem cell-derived cardiomyocytes, enabling high-purity and high-efficiency separation without genetic modification, providing a key technical foundation for cardiac cell therapy.

5. Maglinger, Benton, et al. "Intracranial VCAM1 at time of mechanical thrombectomy predicts ischemic stroke severity." Journal of Neuroinflammation 18.1 (2021): 109. https://doi.org/10.1186/s12974-021-02157-4

Research has found that elevated intracranial and systemic VCAM1 levels in patients with acute large vessel occlusion stroke are significantly associated with hypertension, infarct volume, and poor recovery of neurological function, suggesting that it can serve as a potential therapeutic target.

Creative Biolabs: VCAM1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality VCAM1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom VCAM1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our VCAM1 antibodies, custom preparations, or technical support, contact us at email.